Topical Spiro-oxindole Formulation for Postherpetic Neuralgia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for postherpetic neuralgia are often ineffective for 40% to 50% of patients, and existing therapies lack a good safety profile with minimal systemic exposure, highlighting the need for new topical pain relief options that minimize systemic exposure.
Innovation Solution
A topical pharmaceutical composition containing a therapeutically effective amount of a spiro-oxindole compound, administered periodically to the affected skin area, providing localized relief with minimal systemic exposure by increasing the concentration of the spiro-oxindole compound in the affected dermatome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic analgesic therapies are used to treat postherpetic neuralgia, then pain relief is achieved, but systemic exposure increases leading to safety concerns and drug-drug interactions
Solution Approach 1:
The patent applies local quality by using a topical formulation that delivers the spiro-oxindole compound specifically to the affected dermatome area. This localized delivery achieves effective pain relief at the site of neuralgia while minimizing systemic absorption and associated safety risks, directly resolving the contradiction between efficacy and safety.
Solution Approach 2:
The invention segments the treatment approach by dividing the therapeutic action into localized topical application rather than systemic distribution. The spiro-oxindole compound is delivered specifically to the affected skin area and underlying nerves, separating the therapeutic effect from systemic exposure and reducing harmful side effects.
2Ease of operation
If existing topical analgesics are used, then some pain relief is provided, but 40% to 50% of patients do not respond adequately to treatment
Solution Approach 1:
The patent employs parameter changes by utilizing a spiro-oxindole compound with specific pharmacological properties that enhance sodium channel blocking activity. This chemical parameter change provides superior analgesic efficacy compared to conventional topical agents, overcoming the inadequacy of existing treatments while maintaining the ease of topical application.
3Reliability
If higher concentrations of therapeutic agents are used to improve pain relief, then efficacy increases, but systemic exposure and safety risks increase
Solution Approach 1:
The topical formulation achieves high local concentration of the spiro-oxindole compound at the affected dermatome while maintaining minimal systemic exposure. This localized high concentration provides effective pain relief without the safety risks associated with systemic high-dose therapy, resolving the contradiction between efficacy and safety.
Data Source
AI summary
Methods of treating postherpetic neuralgia in a mammal with a pharmaceutical composition comprising a spiro-oxindole compound of the formula:are disclosed. The methods provide excellent penetration of the spiro-oxindole compound into the affected skin area to effectively reduce the severity of the postherpetic neuralgia and/or to alleviate the postherpetic neuralgia with minimal or negligible systemic exposure of the spiro-oxindole compound.